Quantcast

Reportlinker Adds Liver Disease Treatments: The Global Market Report

September 3, 2009

NEW YORK, Sept. 3 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Liver Disease Treatments: The Global Market

http://www.reportlinker.com/p0128142/Liver-Disease-Treatments-The-Global-Market.html

This Report:

Provides an overview of the global market for liver disease treatments, with market forecasts through 2014

Classifies therapies based on diseases including virus-induced liver disease/Hepatitis, liver tumors, autoimmune liver disorders, congenital liver defects, alcohol-induced liver diseases and chronic liver diseases/Cirrhosis

Offers global forecasts of markets by drug types including antiviral medications such as interferon alpha 2b, pegylated alpha interferon, lamivudine and entecavir, vitamins, antibiotics, penicillamine and calcium

Discusses the future of the industry including the latest development and government regulations

Includes a patent analysis

Profiles leading companies.

Chapter-1: SUMMARY

SUMMARY 4

SUMMARY TABLE GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014 ($ MILLIONS) 6

Chapter-2: OVERVIEW

DEFINITIONS 7

THE LIVER 7

LIVER FUNCTIONS 7

Metabolism 7

Drug Disposition 8

Bile Formation 8

Other Functions 8

COMMON SYMPTOMS OF LIVER DISEASE 8

Jaundice 9

Cholestasis 9

Liver Enlargement 9

Ascites 9

Portal Hypertension 10

Liver Encephalopathy 10

Liver Failure 10

Other Common Symptoms 10

LIVER DISEASES 11

TABLE 1 TYPES OF LIVER DISEASES 11

VIRUS-INDUCED LIVER DISEASE 12

Acute Hepatitis 12

Hepatitis A 13

Hepatitis B 13

Hepatitis C 14

Hepatitis D 14

Chronic Hepatitis 15

Alcohol-induced Chronic Hepatitis 15

Chronic Active Hepatitis 15

Chronic Persistent Hepatitis 15

LIVER TUMORS 16

Benign Liver Tumors 16

Hepatocellular Adenoma 16

Hemangioma 17

Malignant Liver Tumors 18

Hepatocellular Carcinoma 18

Metastatic Liver Cancer 18

CONGENITAL LIVER DEFECTS 19

Biliary Atresia 19

Choledochal Cyst 19

AUTOIMMUNE LIVER DISORDERS 20

Hemochromatosis 20

Wilson’s Disease 21

Autoimmune Hepatitis 22

ALCOHOL-INDUCED LIVER DISEASE 22

Fatty Liver 23

Alcoholic Hepatitis 23

Alcoholic Cirrhosis 24

CHRONIC LIVER DISEASE 24

Cirrhosis 24

Fibrosis 25

NON-ALCOHOLIC FATTY LIVER 26

Chapter-3: REGULATORY ISSUES

TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005-2008 27

TABLE 2 (CONTINUED) 28

TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005-2008 28

FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005-2008 28

TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005-2008 29

TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005-2008 29

Chapter-4: PREVALENCE

UNITED STATES 30

UNITED KINGDOM 31

REST OF THE WORLD 31

PREVELANCE OF A FEW LIVER DISEASES 31

HEPATITIS 31

United States 32

TABLE 6 HEPATITIS BURDEN IN THE UNITED STATES (2005-2006) 32

TABLE 7 INCIDENCE OF ACUTE HEPATITIS BY SEX AND AGE IN THE UNITED STATES (2006) 33

CIRRHOSIS 33

LIVER CANCER OR HEPATOCELLULAR CARCINOMA 33

NON-ALCOHOLIC FATTY LIVER 34

Chapter-5: CLASSIFICATION OF THERAPIES BY DISEASE

VIRUS-INDUCED LIVER DISEASE/HEPATITIS 35

VIRAL VACCINES 35

TABLE 8 VACCINES FOR HEPATITIS A PREVENTION 35

TABLE 9 VACCINES FOR HEPATITIS B PREVENTION 36

ANTIVIRAL DRUGS 36

Nucleoside Analogs 36

TABLE 10 NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS 37

Nucleotide Analogs 37

TABLE 11 NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS 37

TABLE 12 PROTEASE INHIBITORS USED TO TREAT HEPATITIS 38

INTERFERON 38

TABLE 13 INTERFERONS USED TO TREAT HEPATITIS 38

IMMUNE GLOBULINS 39

TABLE 14 IMMUNE GLOBULINS USED TO TREAT HEPATITIS 39

LIVER TUMORS/ LIVER CANCER 39

CHEMOTHERAPEUTIC DRUGS 40

TABLE 15 CHEMOTHERAPUTIC DRUGS USED TO TREAT LIVER CANCER 40

TARGETED THERAPY 41

TABLE 16 TARGETED THERAPY USED TO TREAT LIVER CANCER 41

CONGENITAL LIVER DEFECTS 41

AUTOIMMUNE LIVER DISORDERS 41

TABLE 17 DRUGS USED TO TREAT WILSON’S DISEASE 42

CORTICOSTEROIDS 43

TABLE 18 CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS 43

IMMUNOSUPPRESSIVE AGENTS 43

TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS 43

ANTIMETABOLITES 43

TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS 43

ALCOHOL-INDUCED LIVER DISEASE 44

ANABOLIC STEROIDS 44

TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE 44

ALCOHOL ABUSE DRUGS 44

TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE 44

CHRONIC LIVER DISEASE 44

ANTI-REJECTION MEDICATION 45

TABLE 23 ANTI-REJECTION MEDICATIONS 45

ANTI-INFECTIVES 45

TABLE 24 ANTI-INFECTIVES 45

ANTIFUNGAL PROPHYLAXIS 46

TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS 46

NON-ALCOHOLIC FATTY LIVER 46

GALLSTONE SOLUBILIZING AGENTS 47

TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE 47

OTHER DRUGS 47

TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE 47

Chapter-6: INDUSTRY STRUCTURE

HEPATITIS 48

HEPATITIS VACCINE 48

TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%) 48

FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 49

NUCLEOSIDE ANALOGS 49

TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%) 49

FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%) 50

NUCLEOTIDE ANALOGS 50

TABLE 30 NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER: 2008 (%) 50

FIGURE 4 NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%) 51

INTERFERONS 51

TABLE 31 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%) 51

FIGURE 5 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%) 52

IMMUNE GLOBULINS 52

TABLE 32 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%) 52

FIGURE 6 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%) 53

LIVER TUMORS 53

CHEMOTHERAPY 53

TABLE 33 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%) 53

FIGURE 7 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%) 54

TARGETED THERAPY 54

TABLE 34 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%) 54

FIGURE 8 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%) 55

AUTOIMMUNE DISEASES 55

CHELATING AGENTS 55

TABLE 35 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 55

FIGURE 9 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 56

CORTICOSTEROIDS 56

TABLE 36 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 56

FIGURE 10 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 57

IMMUNOSUPPRESSIVE AGENTS 57

TABLE 37 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 57

FIGURE 11 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 58

ANTIMETABOLITES 58

TABLE 38 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 58

FIGURE 12 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 59

ALCOHOL-INDUCED LIVER DISEASES 59

ANABOLIC STEROIDS 59

TABLE 39 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 59

FIGURE 13 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 60

ALCOHOL ABUSE DRUGS 60

TABLE 40 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%) 60

FIGURE 14 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%) 61

CHRONIC LIVER DISEASE 61

ANTI-REJECTION MEDICATION 61

TABLE 41 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 61

FIGURE 15 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 62

ANTI-INFECTIVES 62

TABLE 42 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 62

FIGURE 16 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 63

ANTIFUNGAL PROPHYLAXIS 63

TABLE 43 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 63

FIGURE 17 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 64

NON-ALCOHOLIC FATTY LIVER DISEASE 64

GALLSTONE STABILIZING AGENTS 64

TABLE 44 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%) 64

FIGURE 18 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%) 65

OTHER DRUGS 65

TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 65

FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%) 66

Chapter-7: DEMAND AND USE

LIFE EXPECTANCY 67

LACK OF KNOWLEDGE 67

LACK OF TREATMENT OPTIONS 67

INCREASING NUMBER OF PATIENTS 68

RESEARCH AND DEVELOPMENT 68

INITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESS 68

INITIATIVES OF VARIOUS ORGANIZATIONS . . . (CONTINUED) 69

Chapter-8: MARKET ANALYSIS

TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS) 70

FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS) 71

HEPATITIS 71

MARKET SIZE 72

TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS) 72

FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS) 73

MARKET OVERVIEW 73

Market Overview (Continued) 74

LIVER TUMORS 75

MARKET SIZE 75

TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS) 76

FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS) 76

MARKET OVERVIEW 76

AUTOIMMUNE DISEASES 77

MARKET SIZE 78

TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS) 78

FIGURE 23 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS) 78

MARKET OVERVIEW 79

ALCOHOL-INDUCED LIVER DISEASE 79

MARKET SIZE 80

TABLE 50 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, THROUGH 2014 ($ MILLIONS) 80

FIGURE 24 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, 2007-2014 ($ MILLIONS) 81

MARKET OVERVIEW 81

CHRONIC LIVER DISEASES 82

MARKET SIZE 82

TABLE 51 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH 2014 ($ MILLIONS) 83

FIGURE 25 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014 ($ MILLIONS) 83

MARKET OVERVIEW 83

NON-ALCOHOLIC FATTY LIVER DISEASE 84

MARKET SIZE 84

TABLE 52 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, THROUGH 2014 ($ MILLIONS) 85

FIGURE 26 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, 2007-2094 ($ MILLIONS) 85

MARKET OVERVIEW 85

Market Overview (Continued) 86

Chapter-9: DRUG-INDUCED LIVER DISEASE

DRUG-INDUCED 87

DRUGS THAT CAN CAUSE LIVER DISEASE 88

ACETAMINOPHEN (TYLENOL) 88

STATINS 89

NICOTINIC ACID (NIACIN) 89

AMIODARONE (CORDARONE) 89

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 89

METHOTREXATE (RHEUMATREX, TREXALL) 90

ANTIBIOTICS 90

TACRINE (COGNEX) 91

DISULFIRAM 91

VITAMIN SUPPLEMENTS 91

TABLE 53 DRUGS THAT CAN CAUSE LIVER DISEASE 91

TABLE 53 (CONTINUED) 92

Chapter-10: NEW DEVELOPMENTS

CLINICAL TRIALS 93

TABLE 54 NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASES 93

TABLE 55 NUMBER OF CLINICAL TRIALS FOR LIVER TUMORS 94

TABLE 56 NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTS 94

TABLE 57 NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS 94

TABLE 58 NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES 95

TABLE 59 NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASES 95

TABLE 60 NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE 95

NEW DEVELOPMENTS 96

NEW DEVELOPMENTS (CONTINUED) 97

STEM CELL RESEARCH 98

Chapter-11: MARKET BY DRUG TYPE

MARKET SIZE 99

TABLE 61 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014 ($ MILLIONS) 99

TABLE 61 (CONTINUED) 100

FIGURE 27 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014 ($ MILLIONS) 101

MARKET SHARE 102

TABLE 62 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008 102

FIGURE 28 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008 (%) 103

VACCINES 103

MARKET SIZE 104

TABLE 63 GLOBAL SALES OF HEPATITIS VACCINE, THROUGH 2014 ($ MILLIONS) 104

FIGURE 29 GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014 ($ MILLIONS) 104

ANTIVIRALS 105

MARKET SIZE 105

TABLE 64 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 105

FIGURE 30 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 106

TABLE 65 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 106

FIGURE 31 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 107

INTERFERONS 107

MARKET SIZE 107

TABLE 66 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 108

FIGURE 32 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 108

IMMUNE GLOBULINS 108

MARKET SIZE 109

TABLE 67 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 109

FIGURE 33 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 109

CHEMOTHERAPY 110

MARKET SIZE 110

TABLE 68 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 110

FIGURE 34 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 111

TARGETED THERAPY 111

MARKET SIZE 111

TABLE 69 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, THROUGH 2014 ($ MILLIONS) 112

FIGURE 35 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, 2007-2014 ($ MILLIONS) 112

CHELATING AGENTS 112

MARKET SIZE 113

TABLE 70 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 113

FIGURE 36 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 113

CORTICOSTEROIDS 114

MARKET SIZE 114

TABLE 71 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 114

FIGURE 37 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 115

IMMUNOSUPPRESSIVE AGENTS 115

MARKET SIZE 115

TABLE 72 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 116

FIGURE 38 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 116

ANTIMETABOLITES 116

MARKET SIZE 117

TABLE 73 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 117

FIGURE 39 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 117

ANABOLIC STEROIDS 118

MARKET SIZE 118

TABLE 74 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 118

FIGURE 40 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 119

ALCOHOL ABUSE DRUGS 119

MARKET SIZE 119

TABLE 75 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, THROUGH 2014 ($ MILLIONS) 120

FIGURE 41 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014 ($ MILLIONS) 120

ANTI-REJECTION MEDICATION 120

MARKET SIZE 121

TABLE 76 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 121

FIGURE 42 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 121

INFECTION-FIGHTING DRUGS 122

MARKET SIZE 122

TABLE 77 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, THROUGH 2014 ($ MILLIONS) 122

FIGURE 43 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, 2007-2014 ($ MILLIONS) 123

ANTIFUNGAL PROPHYLAXIS 123

MARKET SIZE 123

TABLE 78 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, THROUGH 2014 ($ MILLIONS) 124

FIGURE 44 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, 2007-2014 ($ MILLIONS) 124

GALLSTONE SOLUBILIZING AGENTS 124

MARKET SIZE 125

TABLE 79 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH 2014 ($ MILLIONS) 125

FIGURE 45 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014 ($ MILLIONS) 125

OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES 126

MARKET SIZE 126

TABLE 80 GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS) 126

FIGURE 46 GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 127

Chapter-12: PATENT ANALYSIS

CHAPTER 13: PATENT ANALYSIS 128

PATENTS BY YEAR 128

TABLE 81 TOTAL NUMBER OF PATENTS EACH YEAR, 2005-2009 129

FIGURE 47 TOTAL NUMBER OF PATENTS EACH YEAR, 2005-2009 129

PATENTS BY TYPE 129

TABLE 82 NUMBER OF PATENTS BY TYPE, 2005-2009 130

FIGURE 48 NUMBER OF PATENTS BY TYPE, 2005-2009 130

FIGURE 49 PATENTS, SHARE BY TYPE, 2005-2009 (%) 131

PATENTS BY COUNTRY 131

TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009 132

FIGURE 50 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009 132

PATENTS BY COMPANY 133

TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005-2009 133

FIGURE 51 TOTAL NUMBER OF PATENTS BY COMPANY, 2005-2009 134

PATENTS BY ASSIGNEE 134

TABLE 85 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009 135

FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009 135

Chapter-13: COMPANY PROFILES

ABBOTT LABORATORIES 136

ACTAVIS U.S. 136

ALKERMES, INC 137

ALNYLAM PHARMACEUTICALS 137

BARR PHARMACEUTICALS 138

BAYER SCHERING PHARMA AG 138

BIOTEST PHARMACEUTICALS CORPORATION 138

BRISTOL-MYERS SQUIBB 139

CANGENE CORPORATION 140

DEBIOPHARM GROUP 140

ELI LILLY & COMPANY 141

GALMED MEDICAL RESEARCH, LTD. 142

GILEAD SCIENCES, INC. 142

GLAXOSMITHKLINE PLC 143

HUMAN GENOME SCIENCES 143

IDENIX PHARMACEUTICALS INC. 144

KINEMED, INC. 144

MALLINCKRODT 145

MEDA PHARMACEUTICALS 145

MERCK & CO. 146

NOVARTIS AG 146

PAR PHARMACEUTICAL COMPANIES, INC. 147

ROCHE 147

ROXANE LABORATORIES, INC. 148

SANOFI AVENTIS 148

SAVIENT PHARMACEUTICALS, INC. 148

SCHERING-PLOUGH 149

SCYNEXIS 150

TEVA PHARMACEUTICAL INDUSTRIES LTD. 150

THREE RIVERS PHARMACEUTICALS 151

VALEANT PHARMACEUTICALS INTERNATIONAL 152

WATSON PHARMACEUTICALS, INC. 153

WYETH INC. 153

ZYDUS PHARMACEUTICALS INC. 154

ZYMOGENETICS 154

APPENDIX 155

ABBREVIATIONS 155

To order this report:

Liver Disease Treatments: The Global Market

http://www.reportlinker.com/p0128142/Liver-Disease-Treatments-The-Global-Market.html

More market research reports here!

    Contact:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus